CLOs on the Move

NorthStar Medical Radioisotopes

www.northstarnm.com

 
NorthStar® Medical Radioisotopes is a nuclear medicine technology company dedicated to transforming the ways that medical radioisotopes are produced and distributed around the world.
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Mission Pharmacal

Mission Pharmacal is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Perlan Therapeutics Inc

Perlan Therapeutics Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Apexigen, Inc

Apexigen, Inc. is a privately held biopharmaceutical company discovering and developing innovative antibody therapeutics for the treatment of life-threatening and difficult-to-treat diseases. Using its proprietary antibody technology platform, Apexigen has discovered a pipeline of product candidates, which are currently at varying stages of development. The lead product candidate, APX005M, is a novel immuno-oncology antibody that stimulates and enhances an immune response against cancer. Apexigen is developing other product candidates in partnership with four leading biopharmaceutical companies in China. In addition, Apexigen has formed strategic partnerships with multi-national pharmaceutical companies, including Janssen Biotech, Alcon Laboratories and Toray Industries to discover first-in-class antibody lead candidates for the partners' programs.

Advanced Cell Technology

Advanced Cell Technology, Inc. is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Deciphera

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the effectiveness of many cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. Deciphera has developed a diverse pipeline of drug candidates designed to improve outcomes for patients with cancer by enhancing the quality, rate and/or durability of their responses to treatment.